Basimglurant ( DrugBank: Basimglurant )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
158結節性硬化症1

158. 結節性硬化症


臨床試験数 : 112 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05059327
(ClinicalTrials.gov)
March 3, 202120/8/2021Basimglurant in Children, Adolescents, and Young Adults With TSCA Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis ComplexTuberous Sclerosis ComplexDrug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to BasimglurantNoema Pharma AGNULLRecruiting5 Years30 YearsAll54Phase 2United States;Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom